Pfizer acquires AstraZeneca’s small molecule anti-infective business
Pharmaceutical company Pfizer has acquired AstraZeneca’s small molecule anti-infective business, it was announced yesterday.
The buyout will see Pfizer make an upfront payment of $550 million to AstraZeneca, as well as a deferred payment of $175 million in January 2019.
The agreement includes the commercialisation and development rights to Zavicefta (ceftzidime-avibactam), a newly approved EU drug.
Zavicefta specifically addresses multi- drug resistant gram-negative infections.
John Young, group president at Pfizer, said: “The addition of AstraZeneca’s complementary small molecule anti-infectives portfolio will help expand patient access to these important medicines and enhance our global expertise and offerings in this increasingly important area of therapeutics, in addition to providing the opportunity for near-term revenue growth.”
Luke Miels, executive vice president for Europe at AstraZeneca, added: “We’re pleased that our strong science in antibiotics will continue to serve a critical public health need through Pfizer’s dedicated focus on infectious diseases, ensuring these important medicines reach greater numbers of patients around the world.”
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk